Olumiant® (Baricitinib)

Para consultar la información para prescribir completa de Olumiant® (Baricitinib) de clic en el siguiente enlace: Información para prescribir

La información es proporcionada en respuesta a su solicitud, y puede contener datos relacionados a dosis, usos, formulaciones y poblaciones diferentes a la Información para Prescribir del producto. Consulte la Información para Prescribir en la liga que aparece arriba.

Baricitinib: Concomitant Use with Systemic Antibiotics in the RA Phase 3 Clinical Trials

Concomitant antibiotic medications were used in the phase 3 studies of baricitinib for the treatment of rheumatoid arthritis.

MX_cFAQ_BAR307A_CONCOMITANT_ANTIBIOTICS_SYSTEMIC_ RA
MX_cFAQ_BAR307A_CONCOMITANT_ANTIBIOTICS_SYSTEMIC_ RA
es-MX

Description of Baricitinib Rheumatoid Arthritis Phase 3 Clinical Trials

Each of the 4 phase 3 studies in the clinical program evaluated a distinct treatment population of patients with moderate-to-severe RA.

  • RA-BEGIN compared BARI 4 mg monotherapy, BARI 4 mg plus MTX, and MTX monotherapy in patients who had limited or no prior treatment with MTX and were naïve to other DMARDs.1
  • RA-BEAM compared BARI 4 mg vs placebo or adalimumab, with background MTX, in patients with inadequate response to MTX.2 
  • RA-BUILD compared BARI 2 mg and 4 mg vs placebo, with background csDMARD therapy, in patients with inadequate response to csDMARDs.3
  • RA-BEACON compared BARI 2 mg and 4 mg vs placebo, with background csDMARD therapy, in patients with an inadequate response to at least one TNF inhibitor, who may also have had an inadequate response to one or more non-TNF inhibitor biologic DMARDs.4

Potential for Drug-Drug Interactions Based on Pharmacology/Pharmacokinetics Studies

Based on clinical pharmacology studies, no clinically relevant effects on BARI PK occurred with the co-administration of BARI and

  • a CYP3A inhibitor
  • a CYP2C19/CYP2C9/CYP3A inhibitor
  • a CYP3A inducer (rifampicin), or
  • a Pgp inhibitor.5

Co-administration with BARI had no clinically relevant effects on the PK of,

  • a CYP3A substrate
  • a OATP1B1 substrate
  • a Pgp substrate, or
  • an OAT1, OAT3, and BCRP substrate.5,6

Concomitant Use of Antibiotics in Phase 3 Clinical Trials

Concomitant use of antibiotics was permitted in the RA clinical trial program. No analyses have been conducted on the effects on the efficacy and safety of

  • BARI with concomitant antibiotic treatment, or
  • antibiotic treatment with concomitant BARI treatment.6
Concomitant Antibiotic Therapies Administered for Rheumatoid Arthritis in RA-BEAM6

ATC Level 2 Term
(Preferred Name)

Placebo (N=488)
n (%)

BARI 4 mg (N=487)
n (%)

ADA (N=330)
n (%)

Antibacterials for systemic use

91 (18.6)

174 (35.7)

104 (31.5)

Ciprofloxacin

16 (3.3)

34 (7.0)

20 (6.1)

Amoxicillin

17 (3.5)

31 (6.4)

21 (6.4)

Levofloxacin

15 (3.1)

29 (6.0)

18 (5.5)

Amoxicillin w/ clavulanate

11 (2.3)

28 (5.7)

19 (5.8)

Clarithromycin

8 (1.6)

22 (4.5)

10 (3.0)

Azithromycin

10 (2.0)

17 (3.5)

14 (4.2)

Sulfamethoxazole/trimethoprim

4 (0.8)

12 (2.5)

4 (1.2)

Cefalexin

2 (0.4)

10 (2.1)

5 (1.5)

Clindamycin

2 (0.4)

10 (2.1)

5 (1.5)

Cefcapene

2 (0.4)

9 (1.8)

3 (0.9)

Cefdinir

2 (0.4)

8 (1.6)

2 (0.6)

Metronidazole

3 (0.6)

7 (1.4)

5 (1.5)

Norfloxacin

0

6 (1.2)

3 (0.9)

Ampicillin

1 (0.2)

5 (1.0)

1 (0.3)

Cefaclor

1 (0.2)

5 (1.0)

3 (0.9)

Ceftriaxone

3 (0.6)

5 (1.0)

9 (2.7)

Nitrofurantoin

5 (1.0)

5 (1.0)

3 (0.9)

Akritoin

1 (0.2)

4 (0.8)

1 (0.3)

Cefuoxime

2 (0.4)

4 (0.8)

4 (1.2)

Clavulanic Acid

3 (0.6)

4 (0.8)

2 (0.6)

Doxycycline

0

4 (0.8)

3 (0.9)

Cefditoren

3 (0.6)

3 (0.6)

5 (1.5)

Fosfomycin

2 (0.4)

3 (0.6)

2 (0.6)

Garenoxacin

3 (0.6)

3 (0.6)

6 (1.8)

Azo-wintomylon

0

2 (0.4)

0

Cefazolin

0

2 (0.4)

1 (0.3)

Cefpodoxime

1 (0.2)

2 (0.4)

1 (0.3)

Dicloxacillin

0

2 (0.4)

2 (0.6)

Erythromycin

1 (0.2)

2 (0.4)

1 (0.3)

Flucloxacillin

0

2 (0.4)

1 (0.3)

Gentamicin

2 (0.4)

2 (0.4)

1 (0.3)

Moxifloxacin

0

2 (0.4)

1 (0.3)

Sitafloxacin

0

2 (0.4)

0

Sulfamethoxazole

0

2 (0.4)

1 (0.3)

Trimethoprim

0

2 (0.4)

1 (0.3)

Benzylpenicillin

0

1 (0.2)

1 (0.3)

Cefixime

1 (0.2)

1 (0.2)

0

Cefotiam

1 (0.2)

1 (0.2)

0

Cefteram

0

1 (0.2)

0

Josamycin

0

1 (0.2)

0

Lincomycin

0

1 (0.2)

2 (0.6)

Meropenem

0

1 (0.2)

0

Minocycline

1 (0.2)

1 (0.2)

1 (0.3)

Nitroxoline

0

1 (0.2)

0

Ofloxacin

1 (0.2)

1 (0.2)

3 (0.9)

Penicillin Nos

1 (0.2)

1 (0.2)

1 (0.3)

Roxithromycin

0

1 (0.2)

1 (0.3)

Tinidazole

0

1 (0.2)

0

Antibiotics (non-specified)

2 (0.4)

0

0

Cefazolin w/dextrose

0

0

1 (0.3)

Cefprozil

0

0

1 (0.3)

Chloramphenicol

3 (0.6)

0

0

Polymixin E

0

0

1 (0.3)

Ertapenem

1 (0.2)

0

0

Fusafungine

0

0

1 (0.3)

Gatifloxacin

0

0

1 (0.3)

Nalidixic acid

0

0

1 (0.3)

Oxacillin

0

0

1 (0.3)

Oxytetracycline

1 (0.2)

0

1 (0.3)

Phenoxymethylpenicillin

0

0

1 (0.3)

Piperacillin

0

0

1 (0.3)

Pristinamycin

0

0

2 (0.6)

Ribostamycin

0

0

1 (0.3)

Spiramycin

0

0

1 (0.3)

Cefoperazone/Sulbactam

1 (0.2)

0

0

Ampicillin/Sulbactam 

1 (0.2)

0

1 (0.3)

Vancomycin

1 (0.2)

0

2 (0.6)

Abbreviations: ADA = adalimumab; ATC = Anatomical Therapeutic Chemical classification system; BARI = baricitinib.

Note: Preferred names were sorted within the ATC class by descending frequency in the BARI 4-mg group. The table includes data up to rescue or switch from weeks 0 through 52 in the safety population.

Concomitant Antibiotic Therapies Administered for Rheumatoid Arthritis in Study RA-BUILD6

ATC Level 2 Term (Preferred Name)

Placebo (N=228)
n (%)

BARI 2 mg (N=229)
n (%)

BARI 4 mg (N=227)
n (%)

Antibacterials for systemic use

46 (20.2)

47 (20.5)

67 (29.5)

Amoxicillin w/ Clavulanate

6 (2.6)

3 (1.3)

14 (6.2)

Amoxicillin

9 (3.9)

8 (3.5)

13 (5.7)

Azithromycin

8 (3.5)

9 (3.9)

13 (5.7)

Ciprofloxacin

3 (1.3)

12 (5.2)

11 (4.8)

Levofloxacin

7 (3.1)

2 (0.9)

8 (3.5)

Clarithromycin

3 (1.3)

2 (0.9)

7 (3.1)

Cefalexin

1 (0.4)

5 (2.2)

6 (2.6)

Piperacillin w/ Tazobactam

0

1 (0.4)

5 (2.2)

Doxycycline

3 (1.3)

3 (1.3)

4 (1.8)

Nitrofurantoin

1 (0.4)

4 (1.7)

3 (1.3)

Cefixime

0

1 (0.4)

2 (0.9)

Clindamycin

2 (0.9)

0

2 (0.9)

Metronidazole

0

2 (0.9)

2 (0.9)

Moxifloxacin

0

2 (0.9)

2 (0.9)

Norfloxacin

0

1 (0.4)

2 (0.9)

Akritoin

1 (0.4)

1 (0.4)

1 (0.4)

Sulfamethoxazole/ trimethoprim

2 (0.9)

1 (0.4)

1 (0.4)

Cefalotin

0

0

1 (0.4)

Cefazolin

0

1 (0.4)

1 (0.4)

Cefditoren

0

0

1 (0.4)

Cefoperazone

0

0

1 (0.4)

Cefotaxime

0

0

1 (0.4)

Cefotiam

0

0

1 (0.4)

Cefpodoxime

0

0

1 (0.4)

Cefuroxime

1 (0.4)

0

1 (0.4)

Clavulanic acid

0

1 (0.4)

1 (0.4)

Flucloxacillin

2 (0.9)

2 (0.9)

1 (0.4)

Minocycline

0

0

1 (0.4)

Sulbactam

0

0

1 (0.4)

Sulfathiozole

0

0

1 (0.4)

Tinidazole

0

0

1 (0.4)

Ampicillin/Sulbactam

0

0

1 (0.4)

Amikacin

0

1 (0.4)

0

Cefamandole

1 (0.4)

0

0

Cefcapene

1 (0.4)

0

0

Cefdinir

0

1 (0.4)

0

Ceftriaxone

3 (1.3)

2 (0.9)

0

Dexchlorpheniramine

0

1 (0.4)

0

Dicloxacillin

1 (0.4)

0

0

Erythromycin

0

1 (0.4)

0

Fosomycin

2 (0.9)

0

0

Garenoxacin

2 (0.9)

1 (0.4)

0

Lincomycin

0

1 (0.4)

0

Meropenem

1 (0.4)

0

0

Netilmicin

0

1 (0.4)

0

Oxacillin

1 (0.4)

0

0

Polymyxin B

1 (0.4)

0

0

Vancomycin

2 (0.9)

1 (0.4)

0

Abbreviations: ATC = Anatomical Therapeutic Chemical classification system; BARI = baricitinib.
Note: Preferred names were sorted within the ATC class by descending frequency in the BARI 4-mg group. The table includes data up to rescue from weeks 0 through 24 in the safety population.

Concomitant Antibiotics Therapies Administered for Rheumatoid Arthritis in Study RA-BEACON6

ATC Level 2 Term (Preferred Name)

Placebo (N=176)
n (%)

BARI 2 mg (N=174)
n (%)

BARI 4 mg (N=177)
n (%)

Antibacterials for systemic use

32 (18.2)

57 (32.8)

50 (28.2)

Amoxicillin w/ Clavulanate

5 (2.8)

6 (3.4)

13 (7.3)

Azithromycin

3 (1.7)

13 (7.5)

8 (4.5)

Cefalexin

0

4 (2.3)

7 (4.0)

Ciprofloxacin

4 (2.3)

7 (4.0)

7 (4.0)

Amoxicillin

9 (5.1)

6 (3.4)

6 (3.4)

Sulfamethoxazole/ trimethoprim

0

4 (2.3)

5 (2.8)

Moxifloxacin

0

1 (0.6)

4 (2.3)

Ceftriaxone

0

1 (0.6)

3 (1.7)

Cefuroxime

2 (1.1)

2 (1.1)

2 (1.1)

Clarithromycin

3 (1.7)

6 (3.4)

2 (1.1)

Levofloxacin

2 (1.1)

4 (2.3)

2 (1.1)

Minocycline

0

0

2 (1.1)

Ampicillin

0

1 (0.6)

1 (0.6)

Cefadroxil

0

0

1 (0.6)

Cefazolin

1 (0.6)

2 (1.1)

1 (0.6)

Cefapene

0

0

1 (0.6)

Cefixime

0

0

1 (0.6)

Cefprozil

0

0

1 (0.6)

Clindamycin

2 (1.1)

2 (1.1)

1 (0.6)

Doxycycline

0

2 (1.1)

1 (0.6)

Gentamicin

0

0

1 (0.6)

Lomefloxacin

0

0

1 (0.6)

Metronidazole

2 (1.1)

1 (0.6)

1 (0.6)

Nitrofurantoin

0

2 (1.1)

1 (0.6)

Phenoxymethylpenicillin

0

2 (1.1)

1 (0.6)

Piperacillin w/ Tazobactam

2 (1.1)

1 (0.6)

1 (0.6)

Roxithromycin

0

3 (1.7)

1 (0.6)

Vancomycin

0

0

1 (0.6)

Benzylpenicillin

0

1 (0.6)

0

Cefdinir

0

1 (0.6)

0

Cefditoren

1 (0.6)

0

0

Cefmetazole

0

1 (0.6)

0

Dicloxacillin

0

1 (0.6)

0

Erythromycin

0

1 (0.6)

0

Faropenem

1 (0.6)

0

0

Fosfomycin

1 (0.6)

2 (1.1)

0

Fusidic Acid

0

1 (0.6)

0

Garenoxacin

1 (0.6)

0

0

Mecillinam

0

1 (0.6)

0

Meropenem

0

1 (0.6)

0

Norfloxacin

0

1 (0.6)

0

Ofloxacin

0

2 (1.1)

0

Penicillin Nos

1 (0.6)

1 (0.6)

0

Abbreviations: ATC = Anatomical Therapeutic Chemical classification system; BARI = baricitinib.
Note: Preferred names were sorted within the ATC class by descending frequency in the BARI 4 mg group. The table includes data up to rescue from weeks 0 through 24 in the safety population.

Concomitant Antibiotics Therapies Administered for Rheumatoid Arthritis in Study RA-BEGIN6

ATC Level 2 Term
(Preferred Name)

MTX (N=210)
n (%)

BARI 4 mg (N=159)
n (%)

BARI 4 mg + MTX (N=215)
n (%)

Antibacterials for systemic use

49 (23.3)

39 (24.5)

83 (38.6)

Amoxicillin

3 (1.4)

5 (3.1)

21 (9.8)

Amoxicillin w/Clavulanate

7 (3.3)

4 (2.5)

17 (7.9)

Ciprofloxacin

12 (5.7)

10 (6.3)

12 (5.6)

Clarithromycin

4 (1.9)

3 (1.9)

12 (5.6)

Azithromycin

5 (2.4)

4 (2.5)

11 (5.1)

Ceftriaxone

4 (1.9)

2 (1.3)

8 (3.7)

Levofloxacin

6 (2.9)

6 (3.8)

8 (3.7)

Cefuroxime

1 (0.5)

0

5 (2.3)

Doxycycline

1 (0.5)

2 (1.3)

5 (2.3)

Sulfamethoxazole/ trimethoprim

2 (1.0)

0

5 (2.3)

Cefcapene

0

2 (1.3)

4 (1.9)

Clindamycin

0

2 (1.3)

4 (1.9)

Cefdinir

2 (1.0)

0

3 (1.4)

Metronidazole

2 (1.0)

3 (1.9)

3 (1.4)

Nitrofurantoin

0

2 (1.3)

3 (1.4)

Norfloxacin

0

1 (0.6)

3 (1.4)

Vancomycin

2 (1.0)

0

3 (1.4)

Cefalexin

2 (1.0)

1 (0.6)

2 (0.9)

Cefotiam

0

0

2 (0.9)

Erythromycin

0

0

2 (0.9)

Fosfomycin

0

0

2 (0.9)

Garenoxacin

2 (1.0)

0

2 (0.9)

Gentamicin

0

0

2 (0.9)

Ofloxacin

1 (0.5)

0

2 (0.9)

Sitafloxacin

0

0

2 (0.9)

Ampicillin

3 (1.4)

0

1 (0.5)

Antibacterials (non-specified)

0

0

1 (0.5)

Carbenin

0

0

1 (0.5)

Cefazolin

0

0

1 (0.5)

Cefditoren

0

0

1 (0.5)

Cefepime

0

0

1 (0.5)

Dicloxacillin

0

0

1 (0.5)

Duocid (Ampicillin/Sulbactam)

0

0

1 (0.5)

Flucloxacillin

0

1 (0.6)

1 (0.5)

Fusidic Acid

0

0

1 (0.5)

Lincomycin

0

0

1 (0.5)

Lymecycline

0

0

1 (0.5)

Meropenem

0

0

1 (0.5)

Moxifloxacin

1 (0.5)

1 (0.6)

1 (0.5)

Ornidazole

0

0

1 (0.5)

Cefaclor

1 (0.5)

0

0

Cefadroxil

1 (0.5)

0

0

Cefixime

3 (1.4)

0

0

Cefmetazole

1 (0.5)

0

0

Cefpodoxime

0

1 (0.6)

0

Ceftazidime

0

1 (0.6)

0

Clavulanic Acid

1 (0.5)

0

0

Gatifloxacin

1 (0.5)

0

0

Isepamicin

0

1 (0.6)

0

Neomycin

1 (0.5)

0

0

Nitroxoline

0

1 (0.6)

0

Oxacillin

1 (0.5)

0

0

Penicillin Nos

1 (0.5)

0

0

Sulperazon

1 (0.5)

0

0

Telithromycin

1 (0.5)

0

0

Abbreviations: ATC = Anatomical Therapeutic Chemical classification system; BARI = baricitinib; MTX = methotrexate.

Note: Preferred names were sorted within the ATC class by descending frequency in the BARI 4-mg + MTX group. The table includes data up to rescue from weeks 0 through 52 in the safety population.

References

1Fleischmann R, Schiff M, van der Heijde D, et al. Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Rheumatol. 2017;69(3):506-517. http://dx.doi.org/10.1002/art.39953

2Taylor PC, Keystone EC, van der Heijde D, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 2017;376(7):652-662. http://dx.doi.org/10.1056/NEJMoa1608345

3Dougados M, van der Heijde D, Chen YC, et al. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis. 2017;76(9):1634. http://dx.doi.org/10.1136/annrheumdis-2016-210094corr1

4Genovese MC, Kremer J, Zamani O, et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med. 2016;374(13):1243-1252. http://dx.doi.org/10.1056/NEJMoa1507247

5Payne C, Zhang X, Shahri N, et al. Evaluation of potential drug-drug interactions with baricitinib. Ann Rheum Dis. 2015;74(suppl 2):1063. European League Against Rheumatism abstract AB0492. https://doi.org/10.1136/annrheumdis-2015-eular.1627

6Data on file, Eli Lilly and Company and/or one of its subsidiaries.

Glossary

BARI = baricitinib

BCRP = breast cancer resistance protein

csDMARD = conventional synthetic disease-modifying antirheumatic drug

CYP = cytochrome P450

DMARD = disease-modifying antirheumatic drug

MTX = methotrexate

OAT = organic anion transporter

Pgp = P-glycoprotein

PK = pharmacokinetic

RA = rheumatoid arthritis

TNF = tumor necrosis factor

Fecha de la última revisión: 2020 M04 07


Contáctenos para saber más de la información Médica de Lilly

Contacto vía correo electrónico

Correo electrónico: infomed@lilly.com

Envíe su consulta

Escriba su consulta